In vitro activity of ceftolozane/tazobactam against ESBL-producing enterobacterales in China: SMART 2016–2019
The present research underscores the viability of C/T as an alternative to carbapenems for the treatment of ESBL-producing, carbapenem susceptible Enterobacterales. However, the susceptibilities of ESBL-positive CRE to C/T and other studied antimicrobials were consistently below 20%, emphasizing for new innovative treatment strategies.
Authors
- Hui Zhang (ORCID: https://orcid.org/0000-0002-4442-2788)
- Yingchun Xu (ORCID: https://orcid.org/0000-0002-6534-9647)
- Yue Kang (ORCID: https://orcid.org/0000-0002-5301-0523)
- Peiyao Jia (ORCID: https://orcid.org/0000-0003-0585-9255)
- Qiwen Yang (ORCID: https://orcid.org/0009-0008-9652-6950)
- Ying Zhu (ORCID: https://orcid.org/0000-0002-1260-6689)
- Wei Yu (ORCID: https://orcid.org/0000-0001-9526-4559)
Institutions
- Mercy Medical Center (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Shanghai Medical Information Center (CN)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.jgar.2025.02.001
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18